Can hyoscine butylbromide (Buscopan) be used in a patient with focal segmental glomerulosclerosis?

Can Buscopan Be Used in FSGS Patients?

Yes, Buscopan (hyoscine butylbromide) can be safely used in patients with focal segmental glomerulosclerosis (FSGS), as there are no specific contraindications related to glomerular disease or kidney function in general.

Key Considerations

No Direct Contraindication for FSGS

The KDIGO 2021 guidelines for management of glomerular diseases, including FSGS, do not list anticholinergic medications like Buscopan as contraindicated 1, 2. The primary therapeutic concerns in FSGS revolve around immunosuppression (glucocorticoids, calcineurin inhibitors), blood pressure control (ACE inhibitors/ARBs), and proteinuria management—none of which interact adversely with hyoscine butylbromide.

Renal Impairment Considerations

However, exercise caution if the FSGS patient has severe renal impairment. The FDA labeling for Buscopan notes that it is metabolized by the liver and excreted by the kidneys, and studies show increased plasma levels and prolonged half-life in patients with impaired renal function 3. The administration to patients with severe renal impairment cannot be recommended per the drug label 3.

• Practical threshold: If your FSGS patient has an eGFR <30 mL/min/1.73m² or is on dialysis, avoid Buscopan or use with extreme caution
• Mild-to-moderate kidney dysfunction: Generally acceptable with standard dosing, as hyoscine butylbromide has very low systemic bioavailability (<1%) after oral administration 4

Standard Contraindications Apply

The typical contraindications for Buscopan remain relevant regardless of FSGS diagnosis:

• Cardiac instability: Use caution in patients with acute coronary syndrome, uncontrolled heart failure, or recent arrhythmias 5—this is particularly important as FSGS patients may have cardiovascular comorbidities
• Undiagnosed angle-closure glaucoma: While patients with known/treated glaucoma are not at risk, warn all patients to seek immediate medical attention if they develop painful, blurred vision 5, 6
• MAOI use: Absolute contraindication due to risk of elevated blood pressure and serotonin syndrome 3
• Allergic history: Always screen for prior reactions 5

Clinical Context Matters

Buscopan is commonly used in radiology for GI imaging and for treating abdominal cramping/pain 4. In FSGS patients:

• For diagnostic procedures (e.g., barium studies, CT enterography): Safe to use unless severe renal impairment present
• For symptomatic treatment (abdominal pain/cramping): Appropriate if indicated, with renal function monitoring
• Drug interactions: No significant interactions with standard FSGS therapies (corticosteroids, cyclosporine, tacrolimus, ACE inhibitors, ARBs) 3

Practical Algorithm

1. Check renal function: If eGFR >30 mL/min/1.73m² → proceed with standard precautions
2. If eGFR <30 mL/min/1.73m² → avoid or consider alternative (e.g., glucagon for radiological procedures)
3. Screen for cardiac instability: Recent MI, unstable angina, uncontrolled arrhythmias → use alternative
4. Warn about vision changes: Provide written instructions to seek emergency care for eye pain/vision loss
5. Advise not to drive: Until blurred vision resolves (expected anticholinergic effect) 5

Bottom Line

Buscopan is not contraindicated by the presence of FSGS itself. The decision hinges on the degree of renal impairment and standard anticholinergic contraindications. Most FSGS patients with preserved or mildly-to-moderately reduced kidney function can safely receive Buscopan when clinically indicated.